63 results match your criteria: "Allina Health Minneapolis Heart Institute[Affiliation]"
JACC Cardiovasc Interv
December 2024
University of Virginia, Charlottesville, Virginia, USA. Electronic address: https://twitter.com/psorajja.
JACC Cardiovasc Interv
December 2024
Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada. Electronic address:
Despite the challenges associated with periprocedural imaging, transcatheter tricuspid valve interventions have shown important impact on outcomes. A comprehensive understanding of the anatomy of the right heart and surrounding structures is crucial. One way to optimize these interventions is by identifying the optimal fluoroscopic viewing angles along the S-curve of the tricuspid valve.
View Article and Find Full Text PDFAm Heart J Plus
December 2024
University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.
J Am Coll Cardiol
October 2024
Allina Health Minneapolis Heart Institute, Minneapolis, Minnesota, USA.
Circ Cardiovasc Qual Outcomes
November 2024
Cardiology Division, Department of Internal Medicine, O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas (S.R.D.).
Background: Lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease. However, lipoprotein (a) testing remains variable and it is unclear what factors influence testing and if testing changes clinical management.
Methods And Results: A retrospective study using electronic medical record data from 5 health systems identified an atherosclerotic cardiovascular disease cohort divided into those with and without a lipoprotein (a) test between 2019 and 2021.
J Am Coll Cardiol
October 2024
Mount Sinai Health System, New York, New York, USA.
Am Heart J
January 2025
Duke University Hospital, Division of Cardiology, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Background: Although guidelines recommend low-density lipoprotein cholesterol (LDL-C) to be < 70 mg/dL in patients with atherosclerotic cardiovascular disease (ASCVD), the rate of achieving this goal remains suboptimal. We sought to understand real world contemporary practice patterns of LDL-C management in patients with ASCVD, and whether LDL-C testing influenced management across US health systems.
Methods: A retrospective cohort study utilizing electronic medical record data from five health systems participating in the CardioHealth Alliance was performed on patients with an LDL-C measurement in 2021 and prior ASCVD.
Ann Vasc Surg
January 2025
Division of Vascular Surgery, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA.
Background: Transcarotid artery revascularization (TCAR) has emerged as an alternative therapeutic modality to carotid endarterectomy (CEA) and transfemoral carotid artery stenting (TFCAS) for the management of patients with carotid artery stenosis. However, certain issues regarding the indications and contraindications of TCAR remain unanswered or unresolved. The aim of this international, expert-based Delphi consensus document was to attempt to provide some guidance on these topics.
View Article and Find Full Text PDFJ Card Fail
October 2024
Division of Cardiology, Duke University Medical Center, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA; Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. Electronic address:
Circulation
December 2024
Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus (W.T.A.).
J Soc Cardiovasc Angiogr Interv
June 2024
Baylor Heart and Vascular Hospital, Baylor University Medical Center, Dallas, Texas.
JACC Cardiovasc Imaging
August 2024
Department of Medicine, University of Udine, Udine, Italy; Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Pericardial diseases have gained renewed clinical interest, leading to a renaissance in the field. There have been many recent advances in pericardial diseases in both multimodality cardiac imaging of diagnoses, such as recurrent, transient constrictive and effusive-constrictive pericarditis, and targeted therapeutics, especially anti-interleukin (IL)-1 agents that affect the inflammasome as part of autoinflammatory pathophysiology. There remains a large educational gap for clinicians, leading to variability in evaluation and management of these patients.
View Article and Find Full Text PDFJ Am Coll Cardiol
August 2024
Valve Science Center, Minneapolis Heart Institute Foundation, and the Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
JACC Cardiovasc Interv
July 2024
Valve Science Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA; Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA. Electronic address:
ASAIO J
July 2024
From the Cardiology Division, Allina Health - Minneapolis Heart Institute, Minneapolis, Minnesota.
Although current studies support the use of prophylactic distal perfusion catheters (DPCs) to decrease limb ischemia in patients on venoarterial extracorporeal membrane oxygenation (VA ECMO), methods for monitoring limb ischemia differ between studies. We evaluated the safety of a selective rather than prophylactic DPC strategy at a single center with a well-established protocol for limb ischemia monitoring. Distal perfusion catheters were placed selectively if there was evidence of hypoperfusion at any point until decannulation.
View Article and Find Full Text PDFJACC Case Rep
June 2024
Cardiovascular Imaging Research Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
The diagnostic approach toward the management of cardiac implantable electronic device-related tricuspid regurgitation is challenging and undefined. Functional cardiac computed tomography angiography provides a complementary role to echocardiography in the evaluation of lead-leaflet interaction which can help the clinical decision-making process, as presented in this case series.
View Article and Find Full Text PDFEur J Heart Fail
April 2024
Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
JACC Cardiovasc Interv
April 2024
Division of Cardiology, University of Washington Medical Center, Seattle, Washington, USA.
JACC Heart Fail
July 2024
Norton Heart & Vascular Institute, Norton Healthcare, Louisville, Kentucky, USA.
Background: Inadequate inclusion in clinical trial enrollment may contribute to health inequities by evaluating interventions in cohorts that do not fully represent target populations.
Objectives: The aim of this study was to determine if characteristics of patients with heart failure (HF) enrolled in a pivotal trial are associated with who receives an intervention after approval.
Methods: Demographics from 2,017,107 Medicare patients hospitalized for HF were compared with those of the first 10,631 Medicare beneficiaries who received implantable pulmonary artery pressure sensors.
Eur Heart J Acute Cardiovasc Care
May 2024
Division of Cardiology, Willis Knighton Heart Institute, 2400 Hospital Drive #350, Shreveport, LA 71111, USA.
Aims: Despite increased temporary mechanical circulatory support (tMCS) utilization for acute myocardial infarction complicated by cardiogenic shock (AMI-CS), data regarding efficacy and optimal timing for tMCS support are limited. This study aimed to describe outcomes based on tMCS timing in AMI-CS and to identify predictors of 30-day mortality and readmission.
Methods And Results: Patients with AMI-CS identified in the National Readmissions Database were grouped according to the use of tMCS and early (<24 h) vs.
JACC Cardiovasc Interv
March 2024
Allina Health Minneapolis Heart Institute, Minneapolis, Minnesota, USA.
Heart Lung Circ
April 2024
Department of Cardiology, Aswan Heart Centre, Magdi Yacoub Global Heart Foundation, Aswan, Egypt.
Objectives: This pilot study assessed the 12-month angiographic and clinical outcomes of self-apposing (SA) stents in patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
Background: Self-apposing (SA) stents may decrease incomplete strut apposition and stent strut coverage that are common after CTO PCI.
Methods: We compared 20 patients who underwent CTO PCI using SA drug-eluting stents (DESs) with 20 matched control patients who underwent CTO PCI using balloon-expandable (BE)-DESs.